Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US federal appeals court hears arguments in Myriad gene patent case

This article was originally published in SRA

Executive Summary

In a case involving the patentability of isolated DNA, lawyers arguing before the US Court of Appeals for the Federal Circuit on 4 April used hypothetical situations and analogies, for the most part, instead of relying on historical case law on which to base their arguments, with both sides referencing extractions involving everything from baseball bats from trees, to kidneys from the body, to minerals from rocks to get their points across1.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS116103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel